2021 Virtual PGC Series

(1)

D e s i g n a t e d f o r O p h t h a l m o l o g y P h y s i c i a n s & R e s i d e n t s

O R E G O N A C A D E M Y O F O P H T H A L M O L O G Y

417 2nd Street, Ste 101 Lake Oswego, OR 97034 503-222-EYES 11740 SW 68th Pkwy, Ste 100 Portland, OR 97223 503-619-8000

2021 Virtual

PGC Series

October 3

2021

April 5 to

(2)

417 2nd Street, Ste 101 Lake Oswego, Oregon 97034

503-222-EYES (3937) Fax: 503-210-1533 [email protected]

www.OregonEyePhysicians.org

OAO Executive Officers: Julie Falardeau, MD President Jonathan Yoken, MD Vice President Nisha Nagarkatti-Gude, MD, PhD Secretary-Treasurer Jennifer Lyons, MD Past President OAO Education Committee:

Steven Mansberger, MD J. Kevin McKinney, MD, MPH

Andreas Lauer, MD Julie Falardeau, MD OAO Board Members:

Francisco Castillo, MD Mary DeFrank, MD Jason Dimmig, MD Albert Edwards, MD, PhD William Epstein, MD Matthew Hauck, MD Jonathan Kemp, MD Helen Koenigsman, MD Michael Lee, MD Kevin Mundy, MD John Polansky, MD Leah Reznick, MD Christen Richard, MD Eric Suhler, MD, MPH Scot Sullivan, MD Elizabeth Verner-Cole, MD James Wentzien, MD Resident Liaisons: Sarah Glass, MD & Ian Danford, MD

OAO Staff: Amanda Dalton, JD

Executive Director Sabrina Riggs Senior Legislative Advocate

Shelley Shirley Events & Membership

Welcome to the

Oregon Academy of Ophthalmology

2021 Virtual PGC Series

April 5 - October 3, 2021

President’s Welcome Letter

Welcome to OAO’s 2021 Virtual PGC Series! We hope our new virtual program will offer valuable insights into the ever-changing field of ophthalmology. The Academy appreciates the efforts of the Education and Executive Committees who have helped put together this program. We would especially like to thank our Education Committee: Steven Mansberger, MD, J. Kevin McKinney, MD, Julie Falardeau, MD and Andreas Lauer, MD.

We value the contributions made to this conference by our 2021 Sponsors. Please visit our online exhibitor hall to see information on the latest equipment, software, pharmaceuticals and other eye care products available.

When viewing the online content, please sign in with your full legal name and certification and remember to complete the online Course Evaluation in order to receive the AMA PRA Category 1 CreditsTM_you

have earned. Your CME Certificate will be emailed to you. If you have any questions about the program, please do not hesitate to ask me or the OAO staff.

Sincerely,

Julie Falardeau, MD OAO President

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (AACME) through the joint providership of the Oregon Medical Association (OMA) and the Oregon Academy of Ophthalmology. The OMA is accredited by the AACME to provide continuing medical education for physicians.

AMA Credit Statement

The Oregon Medical Association designated this enduring activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

(3)

OAO 2021 VIRTUAL PGC SERIES - COURSE LIST

CATARACT COURSES

FACULTY

CME

Part 1 - Strategies for Complex Cataract Surgery

• Update on IFIS

• Strategies for Co-morbidities with Rock Hard Cataracts

• Precision Pulse Capsulotomy for Complex Cases

David F. Chang, MD

1 Part 2 - Strategies for Complex Cataract Surgery

• Strategies for Phaco with Zonulopathy

David F. Chang, MD

.5

Update on Refractive IOLS

• Explaining Presbyopia Correcting IOL Options

• Prevention and Management of Toric IOL Misalignment

• Light Adjustable IOL

David F. Chang, MD

.5

Lessons Learned from the Greatest Team of Cataract Surgeons

• Lessons Learned

• OR Waste Survey

David F. Chang, MD

.5

RETINA COURSES

FACULTY

CME

Non-Proliferative Diabetic Retinopathy: Should We Treat?

Diana V. Do, MD

.5

Safety of Intravitreal Anti-VEGF Agents: Should We Be Concerned?

Diana V. Do, MD

.5

Which Anti-VEGF Regimen is Best for Your Wet Age-Related Macular

Degeneration Patients?

Diana V. Do, MD

.5

How Will We Treat Wet AMD in 2023?

Diana V. Do, MD

.5

UVEITIS COURSES

FACULTY

CME

Ocular Manifestations of Systemic Autoimmune Diseases

Quan Dong Nguyen, MD

.5

Masquerade Syndrome: Intraocular Lymphoma and Others

Quan Dong Nguyen, MD

.5

Current Concepts in the Diagnosis and Management of Scleritis

Quan Dong Nguyen, MD

.5

Top Five Commonly Made Mistakes in Managing Non-Infectious

Uveitis

Quan Dong Nguyen, MD

.5

NEURO-OPHTHALMOLOGY COURSES

FACULTY

CME

Neuro-Ophthalmic Complications of COVID-19

Marc Dinkin, MD

.5

Venous Sinus Stenosis in Idiopathic Intracranial Hypertension and the

Role for Venous Stenting

Marc Dinkin, MD

.5

Higher Order Cortical Visual Syndromes

Marc Dinkin, MD

.5

(4)

• Better understand the prevention and management of IFIS during

cataract surgery.

• Understand the evidence suppoting routine intracameral moxifloxacin

prophylaxis for cataract surgery.

• Understand the various types of vision loss associated with COVID-19,

including cortical stroke, optic neuritis and papilledema.

• Understand the data arguing for and against a role of venous sinus

stenosis in the pathophysiology of IIH.

• Describe the organization of the post-striate visual processing

pathways into the dorsal and ventral pathways and understand the

basic anatomy of both.

• Understanding the latest clinical trial data o review the benefits and

risks of anti-VEGF therapy or NPDR.

• Learn to recognize the clinical manifestations of intraocular lymphoma.

• Increased ability to diagnose and manage non-infectious uveitis.

• Ability to recognize ocular signs of underling system autoimmune

diseases.

Complete course descriptions and course objectives

are available at www.oregoneyephysicias.org.

(5)

FACULTY DISCLOSURES

Faculty Disclosures

David F. Chang, MD

Carl Zeiss | Consultant

Centricity | Consultant, Investor Eyenovia | Investor

ForSight Vision 6 | Consultant, Investor iDrops | Consultant, Investor

iVantis | Consultant, Investor J&J Vision | Consultant Jellisee | Consultant

Surface | Investor

Versant Ventures | Investor Viewpoint | Consultant, Investor Visionary Ventures II | Investor

Quan Dong Nguyen, MD

Aerie | Consultant, Research Allergan | Consultant Asclepix | Consultant

Boehringer Ingeleim | Consultant, Research EyePoint | Consultant

Genentech | Consultant Gilead | Research

Kodiak | Consultant, Stock Options Mallinckrodt | Consultant

Novartis | Consultant, Research Regeneron | Consultant, Research Santen | Consultant, Research

Marc Dinkin, MD

CareMount Medical (spouse) | Physician (employee)

Diana V. Do, MD

Aerie | Consultant, Research Allergan | Consultant Asclepix | Consultant

Boehringer Ingeleim | Consultant, Research EyePoint | Consultant

Genentech | Consultant Gilead | Research

Kodiak | Consultant, Stock Options Mallinckrodt | Consultant

Novartis | Consultant, Research Regeneron | Consultant, Research Santen | Consultant, Research

Education Committee Disclosures

Andreas Lauer, MD

Steven Mansberger, MD

Allergan | Research Nicox | Consultant Thea | Consultant

Julie Falardeau, MD and J. Kevin McKinney, MD

Nothing to disclose

OAO Staff Disclosures

The following staff report nothing to disclose:

Amanda Dalton, JD, Executive Director Shelley Shirley, Events & Membership

Disclosure Policy

It is the policy of the Oregon Medical Association (OMA) to ensure balance, independence, objectivity, and scientific rigor in its CME activities. To comply with the Standards for Commercial Support of the Accreditation Council for Continuing Medical Education (ACCME), the OMA requires members of the planning committee, applicable staff and faculty to disclose the existence of those commercial interests which produce, market, re-sell, or distribute health care goods or services consumed by, or used on patients with which he/she or their spouse/partner either: a) have a relevant financial relationship now, or b) have had a relevant financial relationship during the past 12 months. Non-profit companies, non-health care related companies and government organizations do not need to be included. Faculty members have declared that they will uphold the OMA’s standards regarding CME activities and that any clinical recommendations are based on the best available evidence or are consistent with generally accepted medical practice. Please indicate in the comments section of the evaluation form whether you detect any instances of bias toward products manufactured by commercial interests.

(6)

David F. Chang, MD | CATARACT

Clinical Professor, Department of Ophthalmology, University of California, San

Francisco, San Francisco, California

Practice: Altos Eye Physicians, Los Altos, California

David F. Chang, MD is a Summa Cum Laude graduate of Harvard College and

Harvard Medical School. He completed his ophthalmology residency at the

University of California, San Francisco where he is now a clinical professor. Having

chaired the ASCRS Cataract Clinical Committee, Dr. Chang has been on the

ASCRS Board and Executive Committee since 2009 and served as the 2012-2013

president. He is a past chair of the AAO Cataract Preferred Practice Pattern Panel

and the AAO Annual Meeting Program Committee. In addition to the Lifetime

AAO Achievement award, Dr. Chang is a 6-time AAO Secretariat Award recipient.

He currently co-chairs the ASCRS Foundation and is the recipient of the 2019

AAO Humanitarian Service Award, and the 2020 Aravind Venkataswamy Award.

Dr. Chang has been honored by the following international societies: AAO

(Kelman Lecture), ASCRS (Binkhorst Medal), ESCRS (Ridley Medal), Asia Pacific

Association of Cataract & Refractive Surgery (Lim Medal), United Kingdom

and Ireland Society of Cataract & Refractive Surgery (Rayner Medal), Canadian

Society of Cataract and Refractive Surgery (Award of Excellence/Stein Lecture),

All India Ophthalmology Society (President’s Lecture), Indian Intraocular Implant

& Refractive Society (Gold Medal), Italian Ophthalmological Society (Strampelli

Medal), International Intraocular Implant Club (IIIC Medal), American-European

Congress of Ophthalmic Surgery (Visionary Award), DOC-German Ophthalmic

Surgeons (DOC Innovator Lecture), Chinese American Ophthalmological Society

(Pioneer Award), International Society of Refractive Surgery (Presidential Award),

Royal Australia and New Zealand College of Ophthalmologists (Gregg Medal),

Asia-Pacific Academy of Ophthalmology (Jose Rizal International Medal), Middle

East Africa Council of Ophthalmology (El-Maghraby International Award), and

the International Council of Ophthalmology (T. Krwawicz Gold Medal). Including

these, he has delivered more than 40 named lectures.

Dr. Chang previously served as chief medical editor of EyeWorld, and Cataract

and Refractive Surgery Today. He was chief editor for Curbside Consultation in

Cataract Surgery (Slack 2007), Mastering Refractive IOLs – the Art and Science

(Slack 2008), Phaco Chop and Advanced Phaco Techniques (Slack 2004, 2012),

and Advanced IOL Fixation Techniques (Slack 2019).

(7)

Diana V. Do MD | RETINA

Vice Chair for Clinical Affairs, Professor of Ophthalmology,

Byers Eye Institute, Stanford University School of Medicine

Practices: Stanford Hospital and Clinics, Lucile Packard Children’s Hospital

University HealthCare Alliance

Palo Alto, California

Diana V. Do, MD, is Professor of Ophthalmology and Vice Chair for Clinical Affairs at the Byers Eye Institute, Stanford University School of Medicine.

Dr. Do is an internationally recognized physician who specializes in the surgical and medical treatment of retinal disorders. Dr. Do is a board-certified ophthalmologist and is an expert in the management of age related macular degeneration, diabetic retinopathy, retinal vein occlusion, retinal detachment, macular hole, retinal infections, and epiretinal membrane. She incorporates state-of-the-art treatment options for her patients while treating each individual with compassion and dignity. Her goal is to provide the highest level of care for each patient.

Dr. Do is a leading clinician-scientist who has authored over 150 publications in the medical literature and has contributed to over 25 book chapters. She has been the principal investigator and co-investigator on more than 45 clinical trials investigating novel treatments for retinal diseases and ocular inflammation. She has been an invited lecturer throughout the North and South America, Europe, and Asia. Furthermore, she has directed and participated in many continuing medical education courses for ophthalmologists and retina specialists throughout the United States.

Before joining Stanford, Dr. Do was Associate Professor of Ophthalmology at the Wilmer Eye Institute, the Johns Hopkins University School of Medicine in Baltimore, Maryland. At Hopkins, she was Head of the Retina Fellowship Training Program. After her tenure at Johns Hopkins, she was recruited to serve as Vice Chair of Education and Professor of Ophthalmology at the University of Nebraska College of Medicine. In addition, she was Program Director of the ophthalmology residency training program and Director of the Retinal Fellowship Training Program at Nebraska.

Dr. Do was educated at the University of California at Berkeley where she graduated summa cum laude with a Bachelor of Arts in Molecular and Cellular Biology. She received her medical degree (Alpha Omega Alpha) and was a Regents Scholar at the University of California San Francisco School of Medicine. After completing her medicine internship at Massachusetts General Hospital / Harvard Medical School, she pursued both her ophthalmology training and retina fellowship at the Wilmer Eye Institute, the Johns Hopkins University School of Medicine.

Dr. Do serves as Vice Chair for Clinical Affairs for the Ophthalmology Department. In addition, she is the Physician Improvement Leader for Quality Improvement (QI) and collaborates on numerous QI projects with faculty to improve patient experience, quality, and access to outstanding eye care at the Byers Eye Institute. She has an active clinical and surgical practice while she continues to investigate novel treatments for retinal diseases. In addition, she teaches students, residents, and retina fellows at Stanford, and she is a member of the Education Committee.

(8)

Quan Dong Nguyen, MD, MSc | UVEITIS

Professor of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine

Practices: Stanford Hospital and Clinics, Lucile Packard Children’s Hospital Palo Alto, California

Born in Saigon, Vietnam, and immigrated with his parents and three brothers to the United States in 1980, Dr. Quan Dong Nguyen currently is Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine.

After completing his education in 2001, Dr. Nguyen joined the faculty at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, as Assistant Professor and then Associate Professor of Ophthalmology and Director of Medical Education. In 2013, he was appointed as the McGaw Endowed Chair in Ophthalmology, Professor and Chairman of the Department of Ophthalmology and the Inaugural Director of the Stanley M. Truhlsen Eye Institute, and Assistant Dean for Translational Research at the University of Nebraska Medical Center.

Dr. Nguyen serves as principal investigator on multiple clinical trials sponsored by the National Eye Institute and other organizations for macular edema (from diabetes and uveitis), neovascular age-related macular degeneration (AMD), and ocular inflammatory and uveitic diseases, as well as co-investigator on numerous other clinical trials involving novel therapeutic agents. Dr. Nguyen is known for his innovative work in early proof-of-concept, first-in-human clinical trials to evaluate potential pharmacotherapeutic agents for retinal vascular and uveitic diseases. Dr. Nguyen and his team were among the first clinician scientists in the world to evaluate aflibercept for neovascular AMD and ranibizumab for diabetic macular edema (DME); the initial results of these studies served as the foundation for subsequent trials leading to the approval of these pharmacologic agents by the FDA and other regulatory authorities for the indicated diseases. Dr. Nguyen has chaired the United States multi-center READ-2, READ-3, and iDEAL studies, evaluating the potential role of VEGF antagonists, through different pathways, for diabetic macular edema.

Dr. Nguyen has lead the SAVE, and the multi-centered SAVE-2, and STOP-UVEITIS studies to evaluate the role of new pharmacologic agents, including specific interleukin inhibition, in uveitis and ocular inflammatory diseases.

At the Byers Eye Institute at Stanford, Dr. Nguyen has an active uveitis and ocular inflammatory diseases as well as clinical and surgical retina practice while he continues his research in pharmacotherapy and ocular imaging. In addition, he teaches and trains students, residents, and clinical and research retina and uveitis fellows at Stanford. Dr. Nguyen is married to Dr. Diana V. Do, who is also Professor of Ophthalmology at Stanford. They have three beautiful daughters: Alexandra, Olivia, and Madelyne, and live in Silicon Valley.

(9)

Marc Dinkin, MD | NEURO-OPHTHALMOLOGY

Helen and Robert Appel Clinical Scholar, Associate Professor of Ophthalmology in Neurology, Associate Professor of Ophthalmology in Ophthalmology, Director of Neuro-Ophthalmology, Director of Neuro-Ophthalmology Fellowship,

Weill Medical College, NY Presbyterian Hospital Practice: Weill Cornell Medicine

New York, NY

Dr. Dinkin is an Associate Professor of Ophthalmology at Weill Cornell Medicine and a member of the Weill Cornell Neurology and Ophthalmology Departments and the Director of the Division of Ophthalmology. He is also Director of the Neuro-Ophthalmology Fellowship.

After graduating from Harvard University and Weill Cornell Medical College, he completed his neurology residency at Weill Cornell Medicine/New York-Presbyterian Hospital, where he was also chief resident. Following that, he completed a clinical fellowship in Neuro-Ophthalmology at the Massachusetts Eye and Ear Infirmary in Boston, MA. Before returning to New York, Dr. Dinkin spent two years as a neuro-ophthalmologist at Harvard Medical School and the Brigham and Women’s Hospital, where he helped develop a Neuro-Ophthalmology fellowship at the hospital and was Associate Director of the Neurology Clerkship. At that time, he also completed the Rabkin Fellowship in Medical Education at Harvard Medical School.

Dr. Dinkin’s research interests include the use of stenting in medically refractory patients with idiopathic intracranial hypertension and venous sinus stenosis, retrograde trans-synaptic degeneration in the visual system and the neuro-ophthalmic complications of COVID-19. He serves on several committees for the North American

Neuro-Ophthalmology Society (NANOS) and is an active educator for the American Academy of Neurology (AAN). He also serves as an Associate Editor for the Journal of Neuro-Ophthalmology and in 2019 was the Guest Editor for the Neuro-Neuro-Ophthalmology Issue of the American Academy of Neurology’s Continuum journal. Dr. Dinkin has been awarded numerous awards for teaching and clinical care, including the Donald D’Amico Award for Ophthalmology, and the J Lawton Smith Award for best research article in the Journal of Neuro-Ophthalmology in 2015 and 2017. Dr. Dinkin lives in Scarsdale with his wife and three children.